OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis $9.81 +0.24 (+2.46%) As of 04/25/2025 12:09 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Santen Pharmaceutical Stock (OTCMKTS:SNPHY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Santen Pharmaceutical alerts:Sign Up Key Stats Today's Range$9.81▼$10.1850-Day Range$8.77▼$10.0952-Week Range$8.65▼$13.00Volume1,223 shsAverage Volume9,790 shsMarket CapitalizationN/AP/E Ratio0.09Dividend Yield492.59%Price TargetN/AConsensus RatingN/A Company OverviewSanten Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.Read More… Santen Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreSNPHY MarketRank™: Santen Pharmaceutical scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Santen Pharmaceutical. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.14.Read more about Santen Pharmaceutical's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Santen Pharmaceutical has recently decreased by 83.33%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSanten Pharmaceutical pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSanten Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Santen Pharmaceutical is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Santen Pharmaceutical's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Santen Pharmaceutical has recently decreased by 83.33%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for SNPHY on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Santen Pharmaceutical is held by institutions.Read more about Santen Pharmaceutical's insider trading history. Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address SNPHY Stock News HeadlinesChina’s NMPA authorises Santen’s glaucoma treatment applicationApril 7, 2025 | msn.comSanten Pharmaceutical to Cancel 5 Million Treasury SharesFebruary 6, 2025 | tipranks.com2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years. April 26, 2025 | Stansberry Research (Ad)Santen Pharmaceutical Co. Revises Year-End Dividend ForecastFebruary 6, 2025 | tipranks.comSanten Pharmaceutical Announces Share Buyback PlanNovember 8, 2024 | markets.businessinsider.comSanten Pharmaceutical Co., Ltd. GAAP EPS of Yen 27.85, revenue of Yen 72.34BAugust 6, 2024 | msn.comHere's what to expect from Santen Pharmaceutical's earnings reportAugust 6, 2024 | markets.businessinsider.comSNPHY Stock Earnings: Santen Pharmaceutical Reported Results for Q4 2023May 17, 2024 | investorplace.comSee More Headlines SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed this year? Santen Pharmaceutical's stock was trading at $10.12 at the start of the year. Since then, SNPHY stock has decreased by 3.1% and is now trading at $9.8050. View the best growth stocks for 2025 here. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today4/26/2025Next Earnings (Estimated)5/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:SNPHY CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,144Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.09 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:SNPHY) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Santen Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.